Esperion Therapeutics ESPR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | -$105.83M-22.0% | -$104.02M-5.6% | -$153.22M-77.1% | ||
| $106K+19.1% | $105K+66.7% | $106K+152% | $106K+152% | $89K+7.2% | ||
| $9.91M-11.7% | $9.87M-17.7% | $10.29M-15.0% | $10.96M-9.1% | $11.22M-8.7% | ||
| $2.9M+64.6% | $3.01M+101% | $2.54M+44.5% | $2.14M+23.1% | $1.76M+2.5% | ||
| $51.06M+91.4% | $60.05M+89.7% | $51.16M+103% | $47.39M+142% | $26.68M+46.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $42.67M— | —— | —— | ||
| $27.29M+39.7% | $31.22M+70.2% | $24.85M+23.1% | $16.65M-6.4% | $19.53M-8.0% | ||
| $43.21M+244% | $30.8M+117% | $25.59M+334% | $23.35M— | $12.55M— | ||
| $38.99M+257% | $25.96M+254% | $15.6M+436% | $1.64M-67.4% | -$24.81M-244% | ||
| —— | —— | -$93.29M— | —— | —— | ||
| $189K-22.5% | $0-100% | $0-100% | $167K+11.3% | $244K+234% | ||
| -$189K+22.5% | $0+100% | $0— | -$167K— | -$244K— | ||
| —— | $0-100% | $24.93M-66.7% | $49.86M0.0% | $74.79M+200% | ||
| —— | $244K+741% | $190.25K+605% | $136.5K+446% | $82.75K+260% | ||
| $59.9M— | $36.18M— | $41.02M— | —— | —— | ||
| $41.53M— | $23.09M— | -$52.27M— | —— | —— | ||
| —— | $16.27M+43.4% | $15.04M+34.7% | $13.81M+25.8% | $12.58M+16.6% | ||
| —— | $612K— | $459K— | $306K— | $153K— | ||
| $2.9M+64.6% | $3.01M+101% | $2.54M+45.0% | $2.14M+23.8% | $1.76M+2.9% | ||
| $106K+19.1% | $105K+66.7% | $106K+152% | $106K+152% | $89K+7.2% | ||
| —— | —— | —— | —— | —— | ||
| $27.29M+39.7% | $31.22M+70.2% | $24.85M+23.1% | $16.65M-6.4% | $19.53M-8.0% | ||
| $43.21M+244% | $30.8M+117% | $25.59M+334% | $23.35M— | $12.55M— | ||
| $58.02M+53.7% | $57.21M+132% | $53.67M+348% | $51.02M— | $37.75M— | ||
| $63.06M+72.5% | $55.06M+111% | $50.11M+206% | $42.61M+466% | $36.56M— | ||
| —— | —— | —— | —— | $7.5M— | ||
| —— | $72.6M-19.9% | $77.12M-4.9% | $81.63M+14.1% | $86.15M+39.0% | ||
| —— | $0-100% | $24.93M-66.7% | $49.86M0.0% | $74.79M+200% | ||
| —— | $244K+741% | $190.25K+605% | $136.5K+446% | $82.75K+260% | ||
| $26.57M— | $10.35M— | —— | —— | —— | ||
| —— | $54.91M-73.9% | $93.71M-40.5% | $132.5M+26.1% | $171.29M+226% | ||
| —— | $612K— | $459K— | $306K— | $153K— | ||
| —— | —— | —— | —— | $60K-67.7% | ||
| —— | —— | -$93.29M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Esperion Therapeutics generate?
- Esperion Therapeutics (ESPR) generated -$86.1M in operating cash flow over the trailing twelve months.
- What is Esperion Therapeutics's free cash flow?
- After $189.0K of capital expenditures, Esperion Therapeutics's free cash flow was -$86.2M over the trailing twelve months, down 129.5% year over year.
- Where does Esperion Therapeutics's cash flow data come from?
- Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
